• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Molecular Biomedicine

    Molecular Biomedicine

    JournalISSN 2662-8651eISSN 2662-8651中科院 医学 2区

    年发文量

    研究主题

    论文(635)

    排序
    1Impaired Glutamatergic Neuron–fibroblast Communication Driving Skin Aging
    Jun-Wei Cao
    2026
    引用
    AI阅读
    加入学术空间
    2Advanced Biomedical Materials and Drug Delivery Systems for Gastrointestinal Applications: Current Understanding and Future Perspectives
    Yijie Hu, Shengjie Luo, Zixin Chen,Rongkang Huang, Feng Wang,Yong Li,Jian Cai

    The gastrointestinal (GI) tract is a major site of ulcerative, inflammatory, and neoplastic diseases. It also functions as an important interface in systemic metabolic regulation. The effectiveness of current treatments is often limited by poor drug stability and short residence times in the GI tract, insufficient exposure at the target site, and unnecessary systemic exposure. These limitations are compounded by regional pH changes, digestive enzymes, mucus turnover, peristaltic clearance, immune surveillance, and microbial metabolism. Advanced biomedical materials, including mucoadhesive hydrogels, stimuli-responsive nanoplatforms, metal–organic frameworks (MOFs), and extracellular matrix (ECM)-derived scaffolds, are increasingly being developed to protect cargo, prolong mucosal residence, enable site-selective release, support tissue repair, and modulate immune or microbial processes. However, selecting a suitable material and delivery strategy for different GI diseases remains challenging. This review examines physiological barriers to drug delivery in the GI tract, classifies advanced biomaterials and delivery systems by therapeutic function and platform type, and evaluates their applications across GI diseases with attention to administration routes, target sites, therapeutic outcomes, and clinical translation. Finally, we discuss future priorities for route-specific material design, human-relevant evaluation, and the safe development of advanced delivery systems. This review aims to provide a practical reference for selecting appropriate biomaterials and delivery systems for GI disease treatment and for guiding their further development toward clinical use.

    2026
    引用
    AI阅读
    加入学术空间
    3The Intracellular Region of Truncated Neurotrophin Receptor TrkB-T1 is Sufficient to Promote Brain Glial Reactivity, Neuroinflammation and Neurotoxicity
    Lola Ugalde-Triviño, María C. Serrano,Margarita Díaz-Guerra

    The development of advanced therapies for stroke, spinal cord injury, and neurodegenerative diseases—primary causes of death, disability and dementia—requires a comprehensive understanding of the interplay between excitotoxicity, aberrant neurotrophic-signalling, glial reactivity, and neuroinflammation. Recent evidence has identified the truncated neurotrophin receptor TrkB-T1 as a potential master regulator of these processes. TrkB-T1 levels increase after stroke whereas the pro-survival full-length isoform (TrkB-FL) decreases. Furthermore, stroke-induced excitotoxicity triggers TrkB-T1 regulated intramembrane proteolysis (RIP), which produces TrkB-T1-ICD, a poorly characterised fragment containing the receptor intracellular domain and a few transmembrane amino acids. This study investigated whether the TrkB-T1 intracellular domain intrinsically contributes to neurotoxicity, reactive gliosis, and neuroinflammation. Our results predict that TrkB-T1 RIP generates a nuclear localization signal in TrkB-T1-ICD that might support nuclear translocation and injury-induced transcriptional regulation in neurons undergoing excitotoxicity. Using cell-penetrating peptides (CPPs), we generated a TrkB-T1-ICD mimetic peptide (Bio-LTT1Ct) containing the TrkB-T1 intracellular region. Bio-LTT1Ct translocated to the nucleus of neurons and astrocytes, provoking cell death and inducing early transcriptional changes in neurons, resembling those triggered by excitotoxicity. In vivo, intranasally administrated Bio-LTT1Ct was brain-permeable and distributed within cortical neurons and astrocytes across both hemispheres. Notably, Bio-LTT1Ct administration was sufficient to promote TrkB isoform imbalance, glial reactivity, and acquisition of proinflammatory profiles, all considered stroke hallmarks. In conclusion, these results imply that TrkB-T1 RIP might be a central mechanism of ischaemic damage and identify the receptor’s intracellular region as sufficient to recapitulate stroke-like effects, marking this pathological mechanism as a critical target for therapy.

    2026
    引用
    AI阅读
    加入学术空间
    4Osteoarthritis: Epidemiology, Risk Factors, Molecular Pathogenesis, Therapeutic Progress, and Future Perspectives
    Kai Huang,Haili Cai

    Osteoarthritis (OA) is a heterogeneous whole-joint disease and a leading cause of pain and disability worldwide. Its development and progression reflect complex interactions among ageing, genetic susceptibility, mechanical stress, inflammation, and metabolic dysfunction. This review integrates current knowledge of OA epidemiology, risk factors, molecular pathogenesis, and therapeutic advances, with particular emphasis on lipid metabolism as an emerging regulator of joint homeostasis. We introduce lipid metabolic coding as a conceptual framework describing how lipid-derived substrates and signals are processed in a context-dependent manner to influence cellular identity, stress responses, and inter-tissue communication. Altered fatty-acid metabolism, de novo lipogenesis, lipid-droplet turnover, cholesterol handling, and post-translational modifications may contribute to cartilage degeneration and whole-joint pathology. We further discuss four overlapping, potentially stage-dependent lipid-associated endotypes as testable models rather than established clinical classifications. Although experimental evidence identifies promising metabolic targets, their causal relevance and therapeutic utility in human OA remain incompletely defined. Integrating longitudinal clinical data with spatial multi-omics and functional validation may clarify these mechanisms and support the development of more precisely targeted, disease-modifying therapies.

    2026
    引用
    AI阅读
    加入学术空间
    5Path2Space for the AI Era: Enabling Large-Scale Spatial Cancer Biomarker Discovery from Routine H&E Images
    Yihao Zhu, Shuangzhou Peng,Jin Ding
    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 635 篇论文

    高被引作者

    作者引用发文
    Aiping Tong9354
    Tang Mei8701
    Guoqing Wang8702
    Jing Zhuang3511
    Sun Chang-Gang3511
    Yuting Zhong3511
    Ping Wang3331
    Yao Xi3331
    XueYan Bian3331
    Weiqiang Lin3331

    高产作者

    作者引用发文
    Long Zhang15013
    Fangfang Zhou15412
    Xiawei Wei869
    Xuelei Ma2465
    Xiao Xu104
    Hua Bao294
    Aiping Tong9354
    Yang Heping94
    Yaling Tang484
    Wu Min434

    相关期刊

    Journal of Tongji Medical University
    Journal of Zhejiang University. Science
    Monoclonal antibodies in immunodiagnosis and immunotherapy
    Molecular & cellular oncology
    Cell stress
    Advances in Immunology
    Reviews of Physiology Biochemistry and Pharmacology
    The Molecular Biology Society of Japan
    生物组学研究杂志(英文)
    Genome Instability & Disease